Ophthalmos Research Team discuss the role of EPA fatty acids and its therapeutic effects on Dry Age Related Macular Degeneration patients.
Dr Tassos Georgiou who is the innovator of the therapy says that the innovative treatment discovered by Ophthalmos Research and Educational Institute will improve the quality of life and reduce the disease burden for individuals and society. There are about 200 million patients with dry AMD with the need of a therapy.
Given the groundbreaking advances in the scientific understanding of the underlying mechanisms of disease by Ophthalmos Research team, the future holds great promise with the therapy to reduce the socioeconomic burden of the disease.
Link: https://www.novapublishers.com/catalog/product_info.php?products_id=55543
